Drug Name Registration in Pakistan: The DRAP Approval Process
Getting a drug's brand name approved by DRAP as part of product registration is a regulatory step under the Drug Act 1976, focused on preventing prescribing confusion — it runs on its own timeline and its own criteria, separate from trademark registration with IPO-Pakistan.
Bringing a new drug product to the Pakistani market means the brand name goes through DRAP's registration process alongside the product itself — a regulatory checkpoint with its own logic, separate from (and not a substitute for) trademark protection.
Where name approval fits in the DRAP process
The proposed brand name is submitted as part of the broader drug registration dossier to the Drug Regulatory Authority of Pakistan, alongside the manufacturing, safety and efficacy data required under the Drug Act 1976. Name approval isn't a separate, standalone application — it moves at the pace of the overall registration.
What DRAP is actually checking for in a proposed name
The core concern is patient safety — DRAP is checking whether the proposed name is confusingly similar to an existing registered product, particularly one used for a different condition or dosage, where a dispensing or prescribing mix-up could cause real harm. This is a different standard from trademark distinctiveness, which is about commercial confusion rather than clinical risk.
Common reasons proposed names get queried
Names that sound or look similar to an existing registered brand, names that could be misread in hurried handwriting or verbal orders, and names that make therapeutic claims the product hasn't been approved to support are the recurring categories of objection we see. Checking a proposed name against the existing register before submission avoids a query that otherwise adds real time to the registration.
Sequencing DRAP and trademark filing
Because DRAP approval and trademark registration are entirely separate processes with separate authorities, we generally recommend filing the trademark application with IPO-Pakistan early — even before DRAP approval is finalised — rather than waiting, since the trademark filing date is what establishes priority against anyone else later filing a similar mark. For more on why both matter independently, see our article on pharmaceutical trademark registration in Pakistan.
For International Law Firms
Referral Partnership
We work with law firms outside Pakistan whose clients need trademark protection here. Firms that commit to referring at least 10 trademark filings a year receive their first 5 trademark applications — including official IPO-Pakistan fees — at no cost, while we build the working relationship.
Discuss a Referral PartnershipThis article is general information about Pakistani law and procedure, not legal advice for any specific matter. If this touches on something you're currently facing, get in touch and we'll advise on your facts directly.